


Figure S3: Influence of OCT1-deficiency on the plasma pharmacokinetics of sorafenib-glucuronide



(A) Plasma sorafenib-glucuronide concentration time curve; (B) liver levels and (C) liver-to-plasma ratios of sorafenib-glucuronide at the end of the experimental sampling period (7.5 h)